Table 1 Characteristics of cohort studied according to PTEN and RAS genotype

From: Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial

Subgroup

Total

PTEN genotype

RAS genotype

  

PTENWT(n=113)

PTENABN(n=32)

Pa

RASWT(n=132)

RASMUT(n=13)

Pa

  

No. (%)b

No. (%)b

 

No. (%)b

No. (%)b

 

Gender

   

0.48

  

0.3

 Male

111

85 (75%)

26 (81%)

 

99 (75%)

12 (92%)

 

 Female

34

28 (25%)

6 (19%)

 

33 (25%)

1 (8%)

 

WBC (x109/l)

   

0.15

  

0.79

 <50

47

41 (36%)

6 (19%)

 

42 (32%)

5 (38%)

 

 50–99

22

17 (15%)

5 (16%)

 

21 (16%)

1 (8%)

 

 ⩾100

76

55 (49%)

21 (66%)

 

69 (52%)

7 (54%)

 

 Median count

110.5

95

135.7

 

108.25

167.1

 

 Range

0.5–881.0

0.5–881.0

0.7–777

 

0.7–881.0

0.5–456.5

 

Age group (years)

   

0.1

  

0.5

 <10

79

56 (50%)

23 (72%)

 

72 (55%)

7 (54%)

 

 15-Oct

47

40 (35%)

7 (22%)

 

44 (33%)

3 (23%)

 

 ⩾16

19

17 (15%)

2 (6%)

 

16 (12%)

3(23%)

 

 Median

9

10

8.5

 

9

9

 

 Range

1–23

1–23

1–18

 

1–23

4–23

 

CNS disease

   

0.04

  

>0.99

 No

135

110 (97%)

28 (88%)

 

125 (95%)

13 (100%)

 

 Yes

7

3 (3%)

4 (12%)

 

7 (5%)

0

 

NCI risk group

   

0.99

  

0.67

 Low

18

14 (12%)

4 (13%)

 

16 (12%)

2 (15%)

 

 High

127

99 (88%)

28 (88%)

 

116 (88%)

11 (85%)

 

Treatment regimen (risk)

   

0.87

  

0.23

 A (low/standard)

13

10 (9%)

3 (9%)

 

11 (8%)

2 (15%)

 

 B (intermediate)

83

66 (58%)

17 (53%)

 

78 (59%)

5 (38%)

 

 C (high)

49

37 (33%)

12 (38%)

 

43 (33%)

6 (46%)

 

Cytogenetics

   

0.86c,d

  

>0.99d

 Normal

28

21 (19%)

7 (22%)

 

26 (20%)

2 (15%)

 

 Abnormal

90

69 (61%)

21 (66%)

 

81 (61%)

9 (69%)

 

 Failed/missing

27

23 (20%)

4 (13%)

 

25 (19%)

2 (15%)

 

Genetic subgroup

   

N/A

  

N/A

 AF10-CALM

3

3 (3%)

0

 

2 (2%)

1 (8%)

 

 LMO2

10

8 (7%)

2 (6%)

 

9 (7%)

1 (8%)

 

 MLL

3

3 (3%)

0

 

3 (2%)

0

 

 TAL1

14

8 (7%)

6 (19%)

 

14 (11%)

0

 

 TLX1

5

4 (4%)

1 (3%)

 

5 (4%)

0

 

 TLX3

15

14 (12%)

1 (3%)

 

11 (8%)

4 (31%)

 

 Other/unclassified

95

73 (65%)

22 (69%)

 

88 (67%)

7 (54%)

 

CDKN2A/B deletion

   

0.29

  

0.2

 No

45

36 (32%)

9 (28%)

 

39 (30%)

6 (46%)

 

 Yes

79

56 (50%)

23 (72%)

 

74 (56%)

5 (38%)

 

 Missing

21

21 (19%)

0

 

19 (14%)

2 (15%)

 
  1. Abbreviations: ABN, abnormal; CNS, central nervous system; NCI, National Cancer Institute; N/A, not applicable; MUT, mutant; WT, wild type; WBC, white blood cell count.
  2. aP-values: Fisher’s exact test unless otherwise indicated.
  3. bPercentages may not add up to 100 owing to rounding up.
  4. cChi squared test.
  5. dExcludes missing/failed.
Back to article page